Fungal Lung Diseases

Subscribe to Selected New Research on Fungal Lung Diseases

32 relevant articles (1 outcomes, 5 trials/studies) found for this Disease

Description: Pulmonary diseases caused by fungal infections, usually through hematogenous spread.

Also Known As:

Lung Diseases, Fungal; Pulmonary Fungal Diseases; Fungal Disease, Pulmonary; Fungal Diseases, Pulmonary; Fungal Infection, Pulmonary; Fungal Infections, Pulmonary; Fungal Lung Disease; Lung Disease, Fungal; Pulmonary Fungal Disease; Pulmonary Fungal Infection; Pulmonary Fungal Infections

Relationship Network

Disease Context: Research Results

Bacterial Infections and Mycoses

Mycoses: 950

Fungal Lung Diseases: 32

Pneumocystis Pneumonia: 1769

Allergic Bronchopulmonary Aspergillosis: 339

Respiratory Tract Diseases: 377

Lung Diseases: 8942

Fungal Lung Diseases: 32

Pneumocystis Pneumonia: 1769

Pulmonary Aspergillosis: 370

Respiratory Tract Infections: 5595

Fungal Lung Diseases: 32

Pneumocystis Pneumonia: 1769

Allergic Bronchopulmonary Aspergillosis: 339

Related Diseases

1.	Neoplasms (Cancer)
2.	Ventilator-Associated Pneumonia (Pneumonia, Ventilator Associated)
3.	Aspergillosis
4.	Primary Myelofibrosis (Myelosclerosis)
5.	Hematologic Neoplasms (Hematological Malignancy)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Fungal Lung Diseases:

1.	Immunoglobulin G (IgG)IBA 08/01/1996 - "Increased IgG antibody responses in serum may provide important information that is helpful in the diagnosis and early treatment of pulmonary fungal infections and in monitoring antifungal treatment." Order ALL the reference details at left...
2.	Amphotericin B (Amphotericin)FDA LinkGeneric 01/01/2002 - "Even with the absence of definitive clinical data, aerosolized administration of amphotericin B may become a viable option for prophylaxis against serious pulmonary fungal infections owing to the severity of disease, lack of serious toxicities associated with this route of administration, and pharmacokinetic and susceptibility data, suggesting a theoretical basis for activity." 03/01/1984 - "We conclude that pulmonary complications and poor prognosis are related to underlying pulmonary fungal infection and not to any interaction between amphotericin B and granulocyte transfusions." 11/01/2008 - "The use of aerosolised amphotericin B (AmB) as prophylaxis or co-adjuvant treatment for pulmonary fungal infections has been reported in several groups of immunosuppressed patients. " 05/01/2001 - "We conclude that pulmonary fungal infections are not a contraindication for allogeneic stem cell transplantation, if non-myeloablative conditioning regimens are used in combination with granulocyte transfusions, intravenous amphotericin B and G-CSF." 04/01/2004 - "OBJECTIVE: To study the therapeutic effect of interleukin-2 (IL-2) and interleukin-12 (IL-12) with and without amphotericin B on pulmonary fungal infection of mice. " Order ALL the reference details at left...
3.	Pulmonary Surfactant-Associated Protein D (Surfactant Protein D)IBA 08/01/1997 - "To determine whether the lung surfactant proteins A (SP-A) and D (SP-D) are involved in the initial protective immunity against opportunistic pulmonary fungal infections caused by Aspergillus fumigatus, we performed a series of in vitro functional studies to see if SP-A and SP-D enhanced binding, phagocytosis, activation, and killing of A. " Order ALL the reference details at left...
4.	Pulmonary Surfactant-Associated ProteinsIBA 08/01/1997 - "To determine whether the lung surfactant proteins A (SP-A) and D (SP-D) are involved in the initial protective immunity against opportunistic pulmonary fungal infections caused by Aspergillus fumigatus, we performed a series of in vitro functional studies to see if SP-A and SP-D enhanced binding, phagocytosis, activation, and killing of A. " Order ALL the reference details at left...
5.	Interleukin-12 (IL 12)IBA 04/01/2004 - "OBJECTIVE: To study the therapeutic effect of interleukin-2 (IL-2) and interleukin-12 (IL-12) with and without amphotericin B on pulmonary fungal infection of mice. " 04/01/2004 - "[An experimental study of the therapeutic effect of interleukin-2 and interleukin-12 with and without amphotericin B on pulmonary fungal infection]" Order ALL the reference details at left...
6.	Sodium Glutamate (Accent)IBA 04/01/2007 - "METHODS: All the cases of clinically diagnosed pulmonary fungal infection from January 2002 to June 2006 were reevaluated according to the definitions of European Organization for Research and Treatment of Cancer/National Institute of Allergy and Infectious Diseases Mycosis Study Group (EORTC/MSG), and the etiology of the patients were analyzed. " Order ALL the reference details at left...
7.	Interleukin-2 (IL2)IBA 04/01/2004 - "OBJECTIVE: To study the therapeutic effect of interleukin-2 (IL-2) and interleukin-12 (IL-12) with and without amphotericin B on pulmonary fungal infection of mice. " 04/01/2004 - "[An experimental study of the therapeutic effect of interleukin-2 and interleukin-12 with and without amphotericin B on pulmonary fungal infection]" Order ALL the reference details at left...
8.	VAP combinationIBA 03/01/2008 - "RESULTS: Of the 127 patients included in this study, 81 (63.78%) were positive and 46 (36.22%) negative for pulmonary fungal infections according to the diagnostic criteria of ventilator-associated pneumonia (VAP). " Order ALL the reference details at left...
9.	liposomal amphotericin B FDA Link 02/01/2002 - "Liposomal amphotericin B (AmBisome): efficacy and safety of low-dose therapy in pulmonary fungal infections." 03/01/1998 - "An open, non-comparative evaluation of the efficacy and safety of amphotericin B lipid complex as treatment of neutropenic patients with presumed or confirmed pulmonary fungal infections." 12/01/1995 - "This experience suggests that nebulised liposomal amphotericin B is well tolerated and merits further assessment in the treatment of pulmonary fungal disease." 02/01/2002 - "A prospective study of the treatment of fungal infections with low-dose AmBisome enrolled 36 of 52 patients with thoracic malignancies who developed pulmonary fungal infections in the National Cancer Centre, Milan, over a 3.5 year period. " Order ALL the reference details at left...
10.	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/01/2002 - "We report the successful use of G-CSF in a renal transplant recipient in whom neutropenia developed following pulmonary fungal infection." 05/01/2001 - "We conclude that pulmonary fungal infections are not a contraindication for allogeneic stem cell transplantation, if non-myeloablative conditioning regimens are used in combination with granulocyte transfusions, intravenous amphotericin B and G-CSF." Order ALL the reference details at left...

Therapies and Procedures

1.	Transplantation (Transplant Recipients) 06/01/2009 - "Pulmonary fungal infections in kidney transplant recipients: an 8-year study." 01/01/1999 - "Pulmonary fungal infection is diagnosed in up to 15-25% of lung transplant recipients and frequently bears a fatal outcome. " 07/01/2004 - "RESULTS: One patient developed AR 17 days after transplantation and 3 patients died on the postoperative days 14, 19 and 23, respectively, due to pulmonary fungal infection, acute hepatic failure or multiple organ failure resulting from stenosis and thrombosis of hepatic artery respectively. " 01/01/2002 - "We report the successful use of G-CSF in a renal transplant recipient in whom neutropenia developed following pulmonary fungal infection." Order ALL the reference details at left...
2.	Drug Therapy (Chemotherapy) 02/01/1982 - "Accurate diagnosis, appropriate drug therapy, and judicious operative intervention when required will achieve gratifying clinical results in the vast majority of pulmonary fungal diseases." 11/01/1994 - "Pulmonary fungal infections have been increasingly reported in the patients with hematologic malignancies treated with aggressive chemotherapy and therefore presenting chemotherapy-induced leukopenia. " 12/01/2005 - "In conclusion, the occurrence of pulmonary fungal infection in malignant hematological diseases is associated with intensive chemotherapy, decrease of neutrophil counts and using of broad-spectrum antibiotics, the diagnosis at early stage is difficult and clinicians should pay more attention to its clinical and laboratory examinations, and give them therapy in time." Order ALL the reference details at left...
3.	Transplants (Transplant) 06/01/2008 - "BACKGROUND: Risk factors, morbidity and mortality from pulmonary fungal infections (PFIs) within the first year after pediatric lung transplant have not previously been characterized. " 11/01/2003 - "Invasive pulmonary fungal infections in solid organ transplant recipients: a four-year review." Order ALL the reference details at left...
4.	Stem Cell Transplantation 05/01/2001 - "We conclude that pulmonary fungal infections are not a contraindication for allogeneic stem cell transplantation, if non-myeloablative conditioning regimens are used in combination with granulocyte transfusions, intravenous amphotericin B and G-CSF." Order ALL the reference details at left...
5.	Lung Transplantation 06/01/2008 - "Increased mortality after pulmonary fungal infection within the first year after pediatric lung transplantation." Order ALL the reference details at left...

Best Treatments:
Research Summary Report
on Fungal Lung Diseases

*WARNING* This specific disease subtype has a relatively small number of significant evidence outcomes. You may proceed to order anyway, or go back to the search field and enter a more general type of the target illness. Once your report has been ordered, however, we can't refund the purchase.

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 1 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>